RESTON, Va., Jan. 22, 2026 /PRNewswire/ -- V2X Inc. (NYSE: VVX) is proud to announce its advancement to Phase II of the US Army's Flight School Next (FSN) competition, as part of the Bell Textron Inc.

You may have missed it due to the firehose of international news over the last week. But in between the CIA director traveling to Venezuela to meet deposed dictator Nicolás Maduro’s replacement and ...

A Metropolitan Transportation Authority rendering shows a conceptual interior of a future Second Avenue Subway station in Harlem, illustrating platform circulation, train clearances and passenger flow ...

President Donald Trump’s administration formally launched the second phase of its plan to end the war between Israel and Hamas this week, shifting from a ceasefire framework toward a post-ceasefire ...

Add Yahoo as a preferred source to see more of our stories on Google. US Middle East envoy Steve Witkoff speaks at the weekly rally at Hostage Square in Tel Aviv, October 11, 2025. (photo credit: ...

OASIS+ is a suite of six multiple-award, indefinite-delivery/indefinite-quantity contracts with a five-year base period and a five-year option term. The contract ...

Michael Block is a 14 time GLAM Award nominated writer, producer, and host of the podcast Block Talk. Throughout his time in the entertainment industry, he has worked on and off Broadway as a stage ...

Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Discov. 23, 656–657; 2024). With ...

Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) released topline data on Wednesday from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with ...

Woodside’s top executive is very bullish about a second development phase on its flagship Sangomar deepwater project offshore Senegal, which is could involve a potential 30-well subsea system.

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a phase 2 study. The U.K.-based pharma had been evaluating the antisense ...

Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called ...